Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review,Bipolar Disorders

当前位置： X-MOL 学术 › Bipolar Disord. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review
Bipolar Disorders ( IF 5.4 ) Pub Date : 2024-02-07 , DOI: 10.1111/bdi.13412
Rakesh Kumar ₁ , Nicolas A. Nuñez ₁ , Neha Joshi ₂ , Boney Joseph ₃ , Alessandra Verde _{4,

5} , Ashok Seshadri ₁ , Alfredo B. Cuellar Barboza ₆ , Larry J. Prokop ₇ , Gustavo C. Medeiros _{8,

9} , Balwinder Singh ₁

Affiliation

Ketamine is increasingly used for treatment-resistant depression (TRD) while its mechanism of action is still being investigated. In this systematic review, we appraise the current evidence of metabolomic biomarkers for racemic ketamine and esketamine in patients with TRD and healthy controls (HCs).

更新日期：2024-02-10

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>